PROF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Profound Medical Corp is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near its pivot at 6.932, technical momentum is mixed to slightly weak, there is no AI Stock Picker or SwingMax buy signal today, and there is no fresh news catalyst. Analyst sentiment remains positive with Buy ratings, but price targets have been trimmed, suggesting some caution. Best decision today is to hold rather than buy aggressively at the current pre-market price of 6.9.
Current price is 6.9 in pre-market, sitting just below the pivot level of 6.932. RSI_6 is 49.853, which is neutral and shows no clear directional momentum. MACD histogram is -0.042 and below zero, with negative contraction, indicating short-term weakness. Moving averages are converging, which usually signals indecision rather than a clean trend. Support is at 6.653 and 6.481, while resistance is at 7.211 and 7.383. The short-term pattern estimate suggests modest upside next day and week, but weakness over the next month.
["Analysts still maintain Buy ratings on the stock.", "Lake Street highlighted upcoming CAPTAIN data as potentially important for prostate cancer and called the prior market reaction misguided.", "The stock is near a technical pivot, so any positive news could move it quickly."]
["No news in the recent week, so there is no immediate catalyst driving the shares.", "Stifel reduced its price target from $12 to $10, showing some moderation in expectations.", "MACD is negative and moving averages are not yet trending upward.", "Options positioning is mildly bearish with a put-call open interest ratio above 1.", "No recent insider, hedge fund, or congress trading signals were reported."]
No usable latest-quarter financial snapshot was provided, so recent revenue or earnings growth cannot be assessed from the supplied data. The latest quarter season was not available in the dataset.
Analyst sentiment is still constructive overall. Stifel lowered its target to $10 from $12 but kept a Buy rating on 2026-05-08. Lake Street also kept a Buy rating and $12 target on 2026-03-09, citing upcoming CAPTAIN clinical data as a major overlooked catalyst. Overall Wall Street tone is bullish, but the recent target cut suggests pros are slightly more cautious on near-term upside.
